Compare WKSP & QNRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WKSP | QNRX |
|---|---|---|
| Founded | 2003 | 2018 |
| Country | United States | United States |
| Employees | 81 | N/A |
| Industry | Auto Parts:O.E.M. | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.2M | 11.6M |
| IPO Year | N/A | 2023 |
| Metric | WKSP | QNRX |
|---|---|---|
| Price | $0.68 | $4.43 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $9.25 | N/A |
| AVG Volume (30 Days) | ★ 544.8K | 26.5K |
| Earning Date | 05-15-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $131.96 | N/A |
| Revenue Next Year | $24.81 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.68 | $4.55 |
| 52 Week High | $4.90 | $41.80 |
| Indicator | WKSP | QNRX |
|---|---|---|
| Relative Strength Index (RSI) | 34.11 | 28.20 |
| Support Level | $0.70 | N/A |
| Resistance Level | $1.03 | $6.84 |
| Average True Range (ATR) | 0.10 | 0.46 |
| MACD | -0.01 | -0.05 |
| Stochastic Oscillator | 8.87 | 14.39 |
Worksport Ltd through its subsidiaries, designs, develops, manufactures, and owns the IP on a variety of tonneau covers, solar integrations, and NP (Non-Parasitic), Hydrogen-based true green energy solutions for the sustainable, clean energy, and automotive industries. The company's product includes soft vinyl tonneau covers and hard aluminum tonneau covers. It operates in two reporting segments for financial reporting purposes: Hard Tonneau Covers and Soft Tonneau Covers. Geographically, the company operates in Canada, United States and Other Countries.
Quoin Pharmaceuticals Ltd is a clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. Its pipeline comprises three products that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Epidermolysis Bullosa, and others.